AstraZeneca touts Imfinzi immunotherapy combos for lung cancer in push to drive PD-L1 drug uptake

AstraZeneca touts Imfinzi immunotherapy combos for lung cancer in push to drive PD-L1 drug uptake

Source: 
Endpoints
snippet: 

Facing the big dogs in the PD-(L)1 space, AstraZeneca has taken its own contender Imfinzi into blockbuster territory in its four years on the market but sees even bigger things for the drug. Combinations could be the key, and early results from a mid-stage test are adding some fuel to that strategy.